Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elranatamab vs Daratumumab + Pomalidomide + Dexamethasone in Relapsed/Refractory Multiple Myeloma
NCT05020236Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Oct 2021
- Primary completion
- Feb 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 26
01
Overview
A Phase 3 trial of elranatamab in multiple myeloma (MM), sponsored by Pfizer. Started Oct 2021; status: recruiting.
02
Drugs
elranatamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05020236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05020236.